Vadova Launch Uncertain Following “Not Approvable” Letter From FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Impax seeks a meeting with the agency after a negative review that included inspection of a contract laboratory.
You may also be interested in...
Next Steps Unclear For Impax Following “Not Approvable” Letter On Vadova For Parkinson’s
FDA is concerned that the name Vadova may cause medication errors caused by confusing the drug with other marketed forms of carbidopa/levodopa.
Next Steps Unclear For Impax Following “Not Approvable” Letter On Vadova For Parkinson’s
FDA is concerned that the name Vadova may cause medication errors caused by confusing the drug with other marketed forms of carbidopa/levodopa.